Sign In
Buy ERAS
$15.08
+1.41 (+10.31%)
At Close: Jun 22, 2026
Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
01:00pm, Tuesday, 16'th Nov 2021 Intrado Digital Media
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Evercore ISI 4th Annual HealthCONx Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a Fireside Chat beginning at 3:05 PM Eastern Time on Thursday, December 2, 2021. The company will also participate in one-on-one investor meetings.
Erasca is Named One of Fierce Biotech's “Fierce 15” Biotechnology Companies of 2021
08:01am, Monday, 27'th Sep 2021
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study
02:55pm, Thursday, 09'th Sep 2021
Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.
Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
08:00am, Thursday, 09'th Sep 2021
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is believed to have broad therapeutic applicability across a wide range of tumor types and indications ERAS-007, a potential best-in-class ERK1/2
Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
04:01pm, Tuesday, 20'th Jul 2021
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
7 Companies Begin Trading. Here's How They're Doing.
02:05pm, Friday, 16'th Jul 2021
The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.
Erasca Announces Pricing of Upsized Initial Public Offering
09:58pm, Thursday, 15'th Jul 2021
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
